Linette Castillo Pichardo
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stilbenes | 5 | 2016 | 44 | 1.460 |
Why?
|
| Vitis | 4 | 2016 | 31 | 1.180 |
Why?
|
| Breast Neoplasms | 6 | 2017 | 1502 | 0.630 |
Why?
|
| Catechin | 3 | 2016 | 31 | 0.570 |
Why?
|
| Quercetin | 3 | 2016 | 45 | 0.560 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 182 | 0.560 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2015 | 421 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 269 | 0.470 |
Why?
|
| Mice | 7 | 2017 | 5913 | 0.410 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 64 | 0.410 |
Why?
|
| Carbazoles | 4 | 2018 | 42 | 0.410 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 156 | 0.400 |
Why?
|
| Quinazolines | 1 | 2012 | 33 | 0.400 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 803 | 0.390 |
Why?
|
| Plant Extracts | 1 | 2013 | 286 | 0.350 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2009 | 23 | 0.340 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 45 | 0.330 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 70 | 0.320 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 2231 | 0.290 |
Why?
|
| rac1 GTP-Binding Protein | 3 | 2018 | 46 | 0.280 |
Why?
|
| Pyrimidines | 3 | 2017 | 118 | 0.250 |
Why?
|
| Cell Proliferation | 6 | 2018 | 1198 | 0.220 |
Why?
|
| Animals | 8 | 2017 | 15081 | 0.170 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 219 | 0.160 |
Why?
|
| Drug Design | 2 | 2018 | 162 | 0.160 |
Why?
|
| Mice, Nude | 3 | 2016 | 337 | 0.160 |
Why?
|
| Signal Transduction | 3 | 2017 | 1908 | 0.150 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 23 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 562 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 127 | 0.140 |
Why?
|
| Mice, SCID | 2 | 2016 | 150 | 0.130 |
Why?
|
| Genistein | 1 | 2016 | 42 | 0.130 |
Why?
|
| Breast | 1 | 2016 | 135 | 0.130 |
Why?
|
| Reference Standards | 1 | 2014 | 52 | 0.130 |
Why?
|
| Calibration | 1 | 2014 | 56 | 0.120 |
Why?
|
| Female | 9 | 2017 | 20969 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 110 | 0.120 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2015 | 22 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 259 | 0.120 |
Why?
|
| Pregnenolone | 1 | 2014 | 10 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 73 | 0.110 |
Why?
|
| Mice, Hairless | 1 | 2013 | 7 | 0.110 |
Why?
|
| p21-Activated Kinases | 1 | 2013 | 16 | 0.110 |
Why?
|
| Molecular Structure | 1 | 2014 | 492 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 40 | 0.110 |
Why?
|
| Apoptosis | 2 | 2012 | 1398 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2016 | 326 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 111 | 0.100 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 14 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 44 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 60 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2012 | 207 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2016 | 426 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 433 | 0.090 |
Why?
|
| Cell Survival | 3 | 2017 | 864 | 0.080 |
Why?
|
| Humans | 8 | 2018 | 37093 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1015 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2009 | 339 | 0.070 |
Why?
|
| Cell Movement | 2 | 2018 | 571 | 0.060 |
Why?
|
| Binding Sites | 2 | 2018 | 651 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2018 | 408 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 409 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 58 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 54 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 275 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 77 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 435 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 177 | 0.030 |
Why?
|
| Aminoquinolines | 1 | 2012 | 14 | 0.030 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 22 | 0.030 |
Why?
|
| Kidney | 1 | 2014 | 337 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 935 | 0.020 |
Why?
|
| Liver | 1 | 2014 | 479 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 295 | 0.020 |
Why?
|